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Autoimmune Neurology
Introduction
GAD (glutamic acid decarboxylase) is a pyridoxal 
5'-phosphate-dependent enzyme, widely expressed 
within the central nervous system and pancreatic 
β-cells, that catalyzes the conversion of the excita-
tory neurotransmitter l-glutamate to the inhibi-
tory neurotransmitter gamma-aminobutyric acid 
(GABA).1 Autoantibodies against GAD were first 
detected in 1988 in a patient with stiff person syn-
drome (SPS), epilepsy and type-1 diabetes melli-
tus (DM-1), pointing out to an immunological 
connection between SPS, DM-1 and epilepsy 
and highlighting since then that disruption of 
GABAergic neurotransmission results in  neuronal 
excitability.2 Over the ensuing years, anti-GAD 
antibodies have been also connected with other 
autoimmune neurological diseases associated with 
neuronal excitability that now comprise the 
“GAD antibody-spectrum disorders” (GAD-SDs) 
and include SPS, autoimmune epilepsy, cerebel-
lar ataxia, limbic encephalitis, myoclous and 
nystagmus.3
As the clinical spectrum of GAD-SD in now wid-
ened and their overlapping symptomatology more 
clearly recognized, a number of puzzling clinical 
connections, diagnostic dilemmas and pathoge-
netic mechanisms have emerged. New informa-
tion about GAD epitopes and the importance of 
GAD titers has further strengthened their speci-
ficity in defining GAD-SD. While low GAD anti-
body titers directed at different epitopes are seen 
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in 80% of patients with DM-1,4 and up to 30% of 
patients with GAD-SD also have DM-1, only 
patients with typical GAD-SD neurological syn-
dromes exhibit very high titers. The paper aims to 
describe the evolved clinical manifestations of 
GAD-SD; discuss why antibody titers matter in 
diagnosis and immunopathogenesis; highlight 
how GABAergic neurotransmission results in 
such diverse clinical phenomena with reciprocal 
inhibition and muscle stiffness; and summarize 
the best therapeutic options to treat autoimmune 
neuronal excitability. Considering that SPS is not 
as rare as has been thought, but still misdiag-
nosed, based on the large number of patients seen 
in our clinic, the review is hoped to increase the 
awareness of these syndromes for practicing neu-




SPS, first described by Moersch and Woltman in 
1956,5 is the commonest and most characteristic 
clinical subtype of GAD-SD. Although its precise 
frequency is unclear, based on the large number of 
patients referred to us in the last 30 years and hav-
ing the opportunity to screen, examine, treat and 
follow many such patients in-person, rather than 
from chart reviews and retrospective data collec-
tion, we believe it is a fascinating disorder, more 
common than previously thought, but still under-
recognized or misdiagnosed. SPS is twice as com-
mon in women than men, frequently represented 
among African-American women, with an average 
age of onset at around 30–35 years.6,7 Patients typ-
ically present with muscle spasms and stiffness, 
concurrently in the thoracolumbar paraspinal and 
abdominal muscles, resulting in difficulties turn-
ing and bending, and progressive muscle rigidity 
with hyperreflexia and spasms, mainly in the trun-
cal and proximal leg muscles.8 Severe truncal stiff-
ness resembles a “statue” or a “freezing”-like 
appearance and patients often describe that they 
walk like a “tin-man”. They often have an accom-
panying severe anxiety, often misdiagnosed as a 
primary anxiety disorder, and task-specific pho-
bias9 that include fear of walking and falling. 
Symptoms of muscle spasms and stiffness can be 
precipitated by unexpected stimuli, including 
sounds, like a phone ringing or a siren, sudden 
touches or emotional upset. In some cases these 
events can cause severe and continuous painful 
spasms, along with stiffness in the thoracic mus-
cles with breathing difficulties, tachycardia and 
hyperhidrosis, a condition we have labeled “status 
spasticus”, requiring emergency admission for 
intravenous diazepam.10 Electrophysiological 
studies have revealed continuous activity of motor 
unit firing at rest, confirming that stiffness is 
caused by co-contractions of agonist and antago-
nist muscles.11–13 Normal physiology is governed 
by reciprocal inhibition, which means that when 
one muscle (i.e. biceps) contracts, its antagonist 
(i.e. triceps) is automatically inhibited. Stimulated 
gamma neurons of the agonist muscle send infor-
mation to the spindles to contract, while the 
antagonist’s gamma neurons do not discharge due 
to inhibition of GABA interneurons (Figure 1). In 
pathologic situations of impaired GABAergic neu-
rotransmission, as occurs in SPS due to reduced 
GABA from the cerebral motor pathways, the 
gamma motor neurons discharge continuously 
because inhibitory signals are inhibited, resulting 
in bursting overstimulation of the muscle spindles 
expressed as simultaneous hypercontraction of 
both agonist and antagonist muscles (Figure 1). 
This is clinically manifested with muscle rigidity 
and stiffness and electrophysiologically as contin-
uous motor unit activity in agonist and antagonist 
muscles. Up to 80% of SPS patients have autoan-
tibodies against GAD, the rate-limiting enzyme 
for GABA synthesis.14 These antibodies may 
interfere in vitro with GABA production and 
in vivo with the entire GABAergic system,15,16 
explaining the unbalanced neurotransmission and 
the ensuing enhanced hyperexcitability expressed 
as spasms and stiffness. Since GAD is also 
expressed in pancreatic cells and patients with 
DM-1 have low-titer anti-GAD antibodies, as dis-
cussed below, up to 35% of SPS patients may also 
have DM-1 along with and other autoimmune 
diseases, such as vitiligo, pernicious anemia, celiac 
disease or thyroiditis.4,17,18
The diagnostic criteria for SPS, as revised in 2009,17 
include: (1) stiffness of the axial muscles, particu-
larly the abdominal and thoraco-lumbar paraspi-
nals, leading to hyperlordosis; (2) superimposed 
painful spasms triggered by unexpected tactile or 
auditory stimuli; (3) severe anxiety with task-spe-
cific phobias especially in anticipation of physically 
challenging tasks; (4) electromyographic evidence 
of continuous motor unit activity of agonist and 
antagonist muscles; (5) absence of other neurologi-
cal findings that may suggest an alternative diagno-
sis; and (6) highly positive GAD-antibody titers by 
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immunocytochemistry, Western blot, enzyme 
linked immunosorbent assay (ELISA) or radioim-
munoassay. Although these criteria best describe 
“classic or typical SPS”, some patients with positive 
anti-GAD antibodies may not exhibit all the afore-
mentioned symptomatology.
In our longitudinal study of 57 anti-GAD-positive 
SPS patients, which represents the largest clinical 
series of personally examined patients every 
6 months for a two-year period to assess disease 
progression, the most common initial symptom 
was the insidious onset of proximal leg stiffness 
followed by rigidity in the lumbosacral paraspi-
nals, thoracic and abdominal muscles. Axial mus-
cle stiffness (truncal and proximal legs), lumbar 
hyperlordosis and impaired gait were first signs in 
68% of these patients with 28% of them also hav-
ing various degrees of facial muscle stiffness.19 
About 15% of the patients with typical SPS symp-
tomatology also had ataxia, dysarthria and 
dysphagia, overlapping with the cerebellar variant, 
as described below, an important distinction 
because these patient subsets do not fully respond 
to immunotherapies.20 Exaggerated reaction to 
various external stimuli and “startle response” 
were present in all patients except two. Marked 
anxiety related to unprotected falls or in anticipa-
tion of physically challenging situations was seen 
in 52 of 57 patients; 21 patients experienced 
chronic anxiety combined with intermittently 
depressed mood. Simple phobias, such as fear of 
walking in open and crowded places, crossing a 
street or taking escalators, were reported by more 
than 10% of patients with several also having task-
related phobias, such as fear of public speaking. 
Most patients had been misdiagnosed with 
 conversion or functional disorder because their 
falls were attributed to avoidant behavior and 
heightened mental anticipation. Other common 
misdiagnoses were myelopathies, dystonias or 
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Figure 1. Reciprocal inhibition and stiffness generation in stiff person syndrome patients.
(a) Normal function: when one muscle is contracted, its antagonist is automatically inhibited. Afferent Ia sensory neuron 
fires, bringing information to the spinal cord, and stimulates the gamma neurons. Then, the  gamma-motor neurons of the 
agonist muscle send signals to the spindle to contract [1], while the gamma motor neurons of the antagonist muscle do not 
discharge (X) due to inhibition of GABA interneuron [3]. As a result, the alpha-motor neuron of antagonist stretches (relaxes) 
the muscle (2) (interneuron: releases inhibitory mediators).
(b) Pathology: if the motor neuron is continuously firing signals, while there is no inhibition of the GABA interneuron to the 
antagonist muscle, the whole muscle will continuously be stimulated and will become hypertonic (spastic), without the 
ability to stretch (relax), due to concurrent contraction of the agonist and the antagonist muscles, as happens in stiff person 
syndrome that presents with stiffness and hyperexcitability.
Therapeutic Advances in Neurological Disorders 14
4 journals.sagepub.com/home/tan
pain along with painful spasms and some had 
been on narcotics.
Although some patients may manifest concurrent 
neuropsychiatric symptomatology that when 
prominent necessitates the need for psychiatric 
advice, others have been labeled as having a func-
tional disorder. Formal neuropsychiatric testing in 10 
consecutive patients seen at the (National Institutes 
of Health NIH) did not meet Diagnostic and 
Statistical Manual for Mental Disorders IV criteria 
for phobic disorder.9 It was felt by our mental health 
colleagues at the National Institutes of Mental 
Health (NIMH) that the patients perceived their 
fears and anxiety as realistic, arising from 
the possibility of falls caused by SPS.10 This still, 
however, remains a puzzling interpretation since 
we do not see such phenomena in other neurologi-
cal disorders that present with weakness and falls.
Apart from the antibodies against GAD, other anti-
bodies may also be positive in patients with SPS 
and hyperexcitability syndromes (Figure 2). We 
had found antibodies against GABAA receptor-
associated protein in about 70% of the patients,19 
but these findings have not been replicated. Another 
autoantibody found in 10–15% of SPS patients is 
against glycine-a1 receptor (GlyR), a key inhibitory 
neurotransmitter. Anti-GlyRa1 antibodies, first 



















Figure 2. Autoantigenic targets associated with the Central Nervous System inhibitory synapses in patients 
with stiff person syndrome.
The pre-synaptic antigens are GAD (1), the enzyme that synthesizes GABA, the main inhibitory neurotransmitter, and 
amphiphysin (2), a synaptic vesicle protein responsible for endocytosis of plasma membranes following GABA release. 
Post-synaptically, the main targets are GABA-A Receptor Associated Protein (GABARAP) (3), gephyrin (4), a tubulin-binding 
protein needed for clustering both GABA-A (5) and glycine receptors (6). The most common antigen in stiff person syndrome 
is GAD followed by glycine receptor (vesicular inhibitory amino acid transporter; VIAAT). Modified from Dalakas.118
GABA, gamma-aminobutyric acid; GAD, glutamic acid decarboxylase.
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rigidity and myoclonus (PERM),21,22 as discussed 
below, may be pathogenic as they recognize extra-
cellular epitopes of the receptor expressed in the 
spinal cord, brainstem and cerebellum. Low-titer 
autoantibodies against GABAA receptor are also 
found in 10% of patients with SPS, cerebellar 
ataxia, epilepsy or encephalitis.3 In about 5% of 
patients, SPS can be paraneoplastic, associated 
with antibodies against amphiphysin23,24 and in a 
single case against gephyrin.25 Apart from GlyR all 
targeted antigens are predominantly cytoplasmic 
and it remains to be determined whether they can 
transiently exhibit an extracellular domain during 
neurotransmission and exocytosis that may account 
for pathogenicity.26
Cerebellar ataxia
Anti-GAD antibody-associated cerebellar ataxia 
is the second most frequently encountered GAD-
related neurological disorder within the GAD-
SDs. It affects more women than men, often with 
comorbid DM1 or polyendocrine autoimmun-
ity.27–31 These patients exhibit gait and limb 
ataxia, nystagmus, severe dysarthria, dysphagia 
and oculomotor dysfunction, most often overlap-
ping with the typical SPS symptomatology that 
worsens the overall clinical picture.32 CSF analy-
sis may show oligoclonal bands, without protein 
elevation, and intrathecal anti-GAD antibody 
synthesis.20,28 Although in an old prospective 
study of 320 patients with sporadic cerebellar 
ataxia only six (2%) had GAD antibodies,33 the 
frequency is probably higher today.
Whether the antibodies play a role in the pathogene-
sis of cerebellar ataxias is unclear.34 Recent studies 
showed that a monoclonal GAD65Ab interferes with 
GABAergic neurotransmission in brain slice prepara-
tions and in vivo elicits in animals neurophysiological 
and behavioral effects mimicking cerebellar ataxias.35 
Intracerebellar administration of IgGs from CSF of 
patients with GAD-associated cerebellar ataxia 
impairs cerebellar modulation of motor control and 
contributes to lack of coordination.36–40 The anti-
GAD antibodies seem to act on nerve terminals of 
GABAergic interneurons depressing the release of 
GABA, resulting in hyperexcitability and eventually 
loss of Purkinje cells with diffuse proliferation of 
Bergmann glia.41,42 Furthermore, a human monoclo-
nal GAD65Ab elicits some pathogenic effects resem-
bling those induced by cerebrospinal fluid (CSF) 
IgGs.35,39 These patients may have overlapping clini-
cal manifestations with epilepsy and SPS.43 The 
magnetic resonance imaging (MRI) of cerebellar 
ataxia patients is normal with rare instances of mild 
cerebellar atrophy,28 implying a functional blockade 
rather than a destructive process, hence the need to 
pursue immunotherapies.17,44
Autoimmune epilepsy
GAD antibodies were first associated with drug 
refractory temporal lobe epilepsy in 1998.45 It is 
considered the third most common GAD65 neuro-
logical autoimmunity, and probably one of the 
most common causes of autoimmune epilepsy.46 In 
early retrospective studies of 200 cases, GAD-
antibodies were most frequent in patients with 
chronic pharmaco-resistant epilepsy, who often 
presented with temporal lobe epilepsy, epilepsia 
partialis continua or refractory convulsive and non-
convulsive status epilepticus,47–49 without inflam-
matory markers in the CSF or MRI but higher 
frequency of autoimmune comorbidities.48,49
In other retrospective series, anti-GAD antibodies 
were detected in 22% of patients with various epi-
lepsies and concurrent autoimmune associations.50 
In a cohort of 233 patients with all types of epi-
lepsy, the percentage of GAD-Abs was only 
2.3%,51 but when dissecting out the patients with 
focal epilepsy, GAD-Abs were present in 16% of 
all cases,52 while among patients with temporal 
lobe epilepsy the percentage was up to 21.7%.53 In 
a series of 1510 epileptic patients, three had musi-
cogenic reflex seizures (MRSs) with two of them 
having GAD-associated epilepsy.54 MRSs have 
also been reported in a patient with SPS comor-
bidity.55 Although this clinical manifestation is 
extremely rare, MRS may be a distinctive type of 
epilepsy highlighted by anti-GAD antibodies, 
necessitating the need to test for GAD antibodies 
in all suspected MRS cases, even with normal 
structural MRI.54 Among 13 children with epi-
lepsy and mean age of 6 years (range 1–13 years), 
seven with suspected autoimmune epilepsy were 
positive for neuronal surface antibodies (N-Methyl-
D-Aspartate Receptors in 3, Voltage Gated 
Potassium Channel-complex in one and GAD in 
another). Immunotherapy in nine neuronal surface 
antibody-positive cases was reported effective.56
Cytotoxic T lymphocytes have been found in histo-
logical preparations of temporomesial tissue from 
patients with pharmaco-resistant epilepsy associ-
ated with GAD antibodies who underwent tempo-
ral lobectomy.57 These T cells may release perforin 
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and granzyme, leading to necrosis, apoptosis or 
electrical silencing of the respective neurons.58 It 
has been suggested on these findings that epilepsy 
may be caused by potentially neurotoxic CD8+ 
cells against GABAergic interneurons.59
The anti-GAD antibodies, by inhibiting GABAergic 
pathways, may result in hyperexcitability, which 
can explain epileptogenesis. The intrathecal syn-
thesis of GAD antibodies has been proposed to 
suggest degeneration of GABAergic neurons and 
release of cytoplasmic proteins into the CSF, lead-
ing to an antibody-mediated immune response.2 
Such a humoral response may potentially inhibit 
the function of GAD, decrease the conversion of 
glutamate to GABA and eventually result in 
excessive excitatory neurotransmission that low-
ers the seizure threshold, contributing to manifes-
tation of drug-resistant epilepsy.60 At least 5% of 
SPS patients have seizures,61,62 although in our 
experience the epilepsy in SPS is not refractory 
but rather easily controlled. On the other hand, 
only a small number of patients with GAD-
associated epilepsy seem to respond to routine 
immunomodulating therapies, requiring more 
aggressive immunosuppressants.59
Limbic encephalitis
Autoimmune limbic encephalitis with anti-GAD 
antibodies clinically presents like the classic auto-
immune or paraneoplastic limbic encephalitis,63 
with impaired working memory, psychiatric 
symptoms, seizures or altered level of conscious-
ness.64 In some patients there are oligoclonal 
bands in the CSF and intrathecal synthesis of 
GAD-Abs65 but the causative role of GAD anti-
bodies remains unclear.
PERM
PERM, described the same year as SPS by 
Campbell and Garland, was considered as an SPS-
spectrum disorder.66 PERM is now a distinct syn-
drome characterized by muscle stiffness, spasms, 
myoclonus and brainstem dysfunction with oculo-
motor abnormalities, dysphagia, gait ataxia promi-
nent autonomic involvement and depressed level of 
consciousness.67 It seems equally present in men 
and women although in our small series all patients 
were men. The hallmark of this disorder is the pres-
ence of anti-GlyR antibodies. As mentioned earlier, 
up to 15% of SPS patients with anti-GAD antibod-
ies also harbor low titers of anti-GlyR-Abs.68–70  
An underlying tumor, especially thymoma or lym-
phoma, can be detected in about 20% of PERM 
patients.71 Another autoantibody detected in four 
patients with PERM is anti-DPPX,62 characterized 
by diverse symptomatology including prominent 
gastrointestinal manifestations, seizures, encepha-
lopathy, sleep disturbance and dysautonomia. 
Limited histological data on PERM has demon-
strated inflammatory and microglial changes and 
cell loss in the pons, medulla, cerebellum, spinal 
cord and autonomic ganglia.8 Some PERM patients 
had increased T2 fluid-attenuated inversion recov-
ery signal of spinal cord and brainstem on MRI.67 
In our small series, PERM is highly responsive to 
immunotherapies, especially if started early.
Nystagmus and abnormal eye movements
Isolated oculomotor dysfunction, characterized 
mainly by downbeat nystagmus and saccadic 
intrusions/oscillations but rarely opthalmoparesis, 
can be also associated with anti-GAD antibodies. 
In our experience, oculomotor dysfunction is not 
unusual among all GAD-positive patients with 
SPS, especially those with cerebellar ataxia.72–75 
The most common isolated GAD-positive oculo-
motor dysfunction is persistent horizontal or 
downbeat nystagmus, presumably related to excit-
ability of vestibular nuclei driving the motor neu-
rons of the ocular muscles, resulting in upward 
slow phase with quick compensatory downward 
phase or horizontal saccades.73,76,77 Within the 
GAD-SDs, opsoclonus and myoclonus have been 
also observed.78,79
The importance of GAD antibody titers  
in the diagnosis of SPS-SD and distinction 
from DM-1
The importance of high GAD titers in connection 
with true neurological syndromes, compared with 
atypical or non-specific entities and DM-1, has 
been recently re-emphasized, pointing out that 
anti-GAD antibody titers do matter for diagnosis, 
even though their pathogenicity is still unclear. 
Patients with the described typical neurological 
diseases within the GAD-SDs normally have very 
high anti-GAD antibody titers compared with 
moderate–low titers in atypical syndromes and 
very low titers in DM-1.74 Several assays are being 
used to detect anti-GAD antibodies, generating 
at times confusion in clinical practice, including 
quantitative radio-immunoassays (RIAs) and 
ELISAs.27,61,80 These assays, initially developed 
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to detect the low titers of GAD antibodies in 
DM-1 patients, require adaptations with serial 
serum dilutions to ensure the accurate detection 
of high titers characteristic of SPS-SD patients. 
Other qualitative assays such as tissue immuno-
histochemistry, cell- based assays or line blots are 
mostly useful to detect structural epitopes of 
GAD65 antibodies.
Depending on the laboratory and the method 
used, reference values may be expressed in differ-
ent units. A major US clinical laboratory uses RIA 
and defines high titers as > or = 20 nmol/L.81,82 
According to their experience, these titers are 
found in classic SPS (93% positive) and in related 
autoimmune neurologic disorders, while values in 
patients who have DM-1 without a polyendocrine 
or autoimmune neurologic syndrome usually have 
titers < or = 20 nmol/L. Other US and European 
laboratories use ELISAs, where the cutoff for posi-
tivity is >5 IU/mL. According to various clinical 
studies in SPS patients, titers are considered high 
when they are above 10,000 IU/mL.74 The same 
applies to our own laboratory where we use ELISA. 
Titers within the range of 5–2000 IU/mL are seen 
in DM-1; only titers >10,000 IU/mL are associ-
ated with a neurologic disorder. In a recent study, 
the significance of serum anti-GAD65 antibody 
titers in connection with true neurological disease 
was re-confirmed by setting a cutoff value of 
10,000 IU/mL in ELISA based on their specificity 
in concurrent testing by immunohistochemistry 
and cell-based assay. High (>10,000 IU/mL) titers 
conferred specificity for an autoimmune neurolog-
ical disease in 94% of the patients, including SPS, 
cerebellar ataxia, chronic epilepsy, limbic encepha-
litis, or overlapping conditions; in contrast, lower 
concentration antibodies were seen in a broader 
spectrum of heterogeneous disorders.83 The high 
titers were also associated with measurable anti-
GAD antibodies in the CSF.
Collectively, the practicing neurologists need to 
be aware that anti-GAD antibody titers do mat-
ter: if high (>10,000 IU/mL), they are diagnostic 
for a true GAD-SD, necessitating immunother-
apy; lower (<10,000 IU/mL) titers are associated 
with atypical or non-specific neurological disor-
ders requiring further investigation, whereas very 
low titers (<2000 IU) are typically seen in DM-1 
or are of unclear significance.74 Importantly, 
GAD-Abs can also be detected within the various 
IVIg preparations and anti-GAD antibodies can 
be detected in patients receiving IVIg.84 Most 
importantly, there is no association between 
GAD-Ab titer and disease severity or response to 
therapy without significant titer reduction after 
immunotherapies with either IVIg or rituximab 
based on two controlled studies we have 
performed.85,86
Intrathecal synthesis of GAD antibodies
There is strong evidence that in SPS, as well as in 
patients with other GAD-SDs, there is intrathecal 
synthesis of GAD antibodies. In a pivotal study, 
using the Link’s formula, the ratio of GAD anti-
body concentration in the CSF to that in the 
serum was divided by the ratio of albumin concen-
tration in the CSF to that in the serum; on this 
basis, values >1 are indicative of robust intrathe-
cal synthesis.57 In clinical practice, when the 
serum GAD antibody titers are above 10,000 IU/
mL, GAD antibodies are also detected in the 
CSF78 and, in these circumstances, a diagnostic 
lumbar puncture may not be necessary, especially 
in SPS patients where the stiffness in the lumbar 
paraspinals requires a radiology-guided puncture.
The demonstration, however, of intrathecal GAD 
antibody synthesis comprises the strongest evi-
dence linking a neurological syndrome to autoim-
munity, as suggested.87 In clinical practice, testing 
the CSF for GAD antibodies is helpful in patients 
with serum titers below 10,000 IU/mL and in 
patients with seronegative GAD-spectrum disor-
der, especially those with encephalitis, and in 
patients with a seemingly functional disorder 
resembling SPS symptomatology.
GAD epitopes and their potential 
significance
GAD exists in two isoforms, GAD65 and GAD67, 
each encoded by a different gene, GAD1 and 
GAD2, located in chromosomes 2q31.1 and 
10p12, respectively.88 GAD65 represents the 
membrane form of the enzyme. It is found in syn-
aptic vesicles in the nerve endings and it is mostly 
utilized under circumstances where there is an 
urgent need of GABA synthesis and release.89,90 
GAD67 represents the soluble form, it is abundant 
in the cytoplasm and it is implicated in functions 
such as synaptogenesis, but not neurotransmis-
sion. The two isoforms are divided according to 
their linear sequence into three functional domains: 
Therapeutic Advances in Neurological Disorders 14
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an amino(N)-terminal domain, amino acids-aa 
1-188 (1-197); a middle PLP-binding domain, 
where the catalytic center of the enzyme resides, aa 
189-464 (198-473), and a carboxy (C)-terminal 
domain, aa465-585 (474-594).91 The isoforms 
show an overall similarity within the middle and 
C-terminal domains, having 74% identity, while 
the N-terminals have 25%.4 More specifically, 
patients with SPS and cerebellar ataxia show 
strong immunoreactivity to b78 epitopes, whereas 
those with DM-1 recognize more commonly the 
b96.11 epitopes.87,92,93 Antibodies against b78 
inhibit the enzymatic activity of GAD and provoke 
depression in the inhibitory synapsis in rat cerebel-
lar slices, whereas these events are not observed 
with antibodies against the b96.11 epitope.35 
Patients with DM-1 harbor antibodies directed 
against conformational epitopes exclusively located 
in the PLP- and C-terminals domains.94,95 In con-
trast, patients with SPS predominantly recognize 
linear epitopes in all three domains96,97 and in the 
first 100aa that constitute the regulatory sequence 
in the N-terminal domain of GAD65 and does not 
react with DM-1 sera.92,98–101 The GAD-Abs 
therefore in SPS exhibit a different epitope pattern 
of antibody reactivity with distinct biological 
effects, compared with DM-1.
Whether different epitope patterns exist among 
GAD-related syndromes is unclear. In one study, 
GAD-Abs from patients with limbic encephalitis 
were more likely to recognize epitopes in the 
N-terminal domain, compared with those with 
SPS, cerebellar ataxia or epilepsy, with the latter 
showing more reactivity to the C-terminal domain 
of the enzyme.35,102 In our study, however, of 27 
patients with diverse GAD-related syndromes, no 
differences in epitope specificities were found 
except in three patients with epilepsy.103 
Accordingly, the current data cannot explain the 
diverse clinical presentation based on different 
epitope binding patterns.
Diagnostic work-up and concerns in 
diagnosing GAD-negative SPS
The diagnostic work-up for SPS includes the clin-
ical criteria mentioned earlier in conjunction with 
electrophysiological data, and relevant autoanti-
body seropositivity mainly highlighted by anti-
GAD with cutoff titers >10.000 IU/mL by 
ELISA, as mentioned earlier (Table 1).15,104 The 
main difficulty remains the seronegative SPS that 
represents close to 20% of patients with seem-
ingly clinical SPS. Considering that functional 
components can co-exist in some patients with 
high-GAD titers, the main concern in practice is 
to ensure that patients with seronegative SPS do 
not have a functional disorder or another neuro-
logical disease mimicking SPS. Adherence to 
strict clinical criteria, neurophysiologic testing 
and neuropsychiatric assessment, if needed, are 
essential. Although an empirical trial with diaze-
pam is often used, it does not ensure diagnostic 
accuracy because it cannot differentiate an 
organic from a functional disorder.
Pathogenesis of GAD-SD and biologic basis 
of autoimmune hyperexcitability
The pathogenesis of GAD-associated syndromes 
is still uncertain. Despite the key role of 
Table 1. Diagnostic work-up.




triggered by unexpected 
external stimuli or 
emotional upset
•   No other neurological 
diseases that could 
account for stiffness
Continuous co-
contraction of agonist 
and antagonist muscles 
with inability to relax
Sera and CSF (when applied) are 







GAD seronegative patients need to be 




required, for the Diagnostic 
and Statistical Manual for 
Mental Disorders (DSM-IV) 
Axis I (SCID-I/P) to explore 
the origin of anxiety and 
phobic symptoms
CBA, Cell-based Assay; CSF, cerebrospinal fluid; ELISA, enzyme linked immunosorbent assay; GABAA, gamma-aminobutyric acid A; GAD, glutamic 
acid decarboxylase; GlyR, glycine-a1 receptor.
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auto antibodies in defining a rather heterogeneous 
group of overlapping disorders, it is not yet clear 
whether GAD antibodies are pathogenic or mark-
ers of aberrantly activated innate and acquired 
immunity.
Rats treated intracerebroventricularly with SPS-
IgG showed a stiffness-like behavior, a decline of 
motor function as measured by time on the 
Rotarod test and a decrease in forelimb grip 
strength as compared with control IgG-infused 
rats. Additional studies of passive transfer of 
GAD-Abs from patients into rats or mice have 
shown continuous motor activity with repetitive 
muscle discharges and abnormally enhanced 
reflexes with increased excitability of anterior 
horn cells.38,39,105 Whether these effects are related 
to anti-GAD or other antibodies directed at dif-
ferent synaptic antigens is unclear. On the other 
hand, diffusion of IgG and quantification of 
enhanced green fluorescent protein-labeled neu-
rons after SPS IgG injection into mice did not 
generate any symptoms.106 Furthermore, stereo-
tactic injection of GAD-Abs into the hippocam-
pus of rats in vivo did not alter spontaneous and 
evoked GABAergic synaptic transmission.107,108 
In contrast to anti-GAD antibodies, animals 
treated intraperitoneally109 or intrathecally110 with 
IgG anti-amphiphysin Abs have exhibited stiff-
ness-like behavior.
Equally controversial are the data from experi-
ments conducted in cultured neurons. 
Hippocampal cultured neurons treated with sera 
from epileptic GAD-positive patients showed an 
increase of post-synaptic inhibitory potentials 
compared with negative controls.111 Further, 
when rat cerebellar slices were exposed to serum 
or CSF from patients with SPS or cerebellar 
ataxia, a decrease of post-synaptic inhibitory 
currents of Purkinje cells was observed, com-
pared with GAD-negative sera form ataxic 
patients.72,112,113 Some studies have also shown 
epitope-dependent pathogenic actions of GAD-
Abs in histological brain sections and in vivo 
preparations,35,106,114 whereas others showed 
lack of internalization into hippocampal cultured 
rat neurons3 (Table 2). It remains, however, 
unclear how GAD-Abs can cause the GABAergic 
dysfunction in SPS if not internalizing into neu-
rons. The possibility that antigens during synap-
tic transmission transiently expose extracellular 
epitopes, recognized by the immune system, 
remains hypothetical.
Circulating GAD-reactive B cells that can differ-
entiate into antibody producing cells have been 
also detected in the peripheral blood and bone 
marrow of patients with GAD-Ab associated neu-
rological syndromes. Interestingly, the presence 
of GAD was not required for induction of GAD-
antibody producing cells and GAD-Ab produc-
tion by stimulated peripheral blood cells did not 
correlate with GAD-Ab serum levels, suggesting 
an additional source of GAD-Abs. This study 
implied that targeting both memory B cells (i.e. 
with rituximab) and plasma cells (i.e. with borte-
zomib) might be a potential treatment option.115
Anti-GAD antibodies are typically found in the 
peripheral blood and in lower levels in the CSF.15 
GAD-Abs in CSF on occasion can be detected as 
monoclonal bands, suggesting that only a fraction 
of the whole anti-GAD response occurs in the 
CNS and that the intrathecal production of 
GAD-Abs could facilitate their access to relevant 
neuronal autoantigens. Interestingly, the intrath-
ecal monoclonal IgGs are reactive to GAD65.3,4 
The role of B cells remains, however, unclear. 
The statistically negative controlled study with 
rituximab (see below) cannot be interpreted to 
suggest that B cell suppression and antibody pro-
duction may not be critical factors, because the 
study had an impressive effect in some patients 
but it was statistically negative due to a strong 
placebo effect. The same may also apply to the 
lack of correlation of antibodies titers to disease 
severity. Interestingly, it has been observed that 
mice possessing a monoclonal GAD65 specific 
CD4+ T cell population develop a lethal enceph-
alomyelitis-like disease in the absence of any other 
T cells or B cells.116
Therapeutic approaches
SPS patients experience severe anxiety and 
depression due to phobias of sustaining falls or 
inability in completing even simple physical tasks. 
Patients with significant symptoms that do not 
improve concurrently with the physical symptom-
atology need clinical and psychological support 
both at home and at work. Their phobias often 
lead to depression, or at times addiction to drugs 
such as benzodiazepines or narcotics, highlighting 
the need for multifactorial care.
For SPS and GAD-SD, two strategies of treatment 
are implemented: symptomatic (anti- spasmodic) or 
immunologic117 interventions either independently 
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or in combination, depending on symptom severity 
(Table 3). Symptomatic relief is often achieved 
with agents that enhance GABAergic transmission, 
such as benzodiazepines, which diminish spasms 
and stiffness, especially those triggered by emo-
tional factors. The first therapeutic option is diaze-
pam, a GABAA agonist. This drug can help most 
patients, although the high doses sometimes 
required cannot be tolerated and may lead to addic-
tion. Other similar compounds include clonaze-
pam, alprazolam, lorazepam and temazepam. The 
second category of drugs used as anti-spasticity 
agents are GABAB agonists. Because of better tol-
erance and no addiction potential, we have now 
started using these agents as first line therapy in lieu 
of benzodiazepines. The most effective among 
them is baclofen, to the point of now using it as first 
in order. Sometimes high doses (up to 60 mg) are 
required to induce meaningful improvement, 
resulting in some cognitive issues. Antiepileptic 
drugs that enhance the brain’s GABAergic trans-
mission also improve symptomatology, either alone 
Table 2. Experimental animal models of glutamic acid decarboxylase antibody-spectrum disorder.
Experimental approach Sample Clinical 
manifestation
Result Reference
(a)  Stereotactical injection 
into rats’ hippocampi
CSF Focal epilepsy due 
to LE
NO changes on GABAergic 
transmission
Hackert et al.107
(b)  Intraperitoneal injection 
into transgenic mice
IgG PERM and SPS NO differences in behavioral 
tests
NO loss of GAD-EGFP neurons
Chang et al.106
(c)  Epitope specificity: 
monoclonal GAD Ab in 
cerebellar slices and mice
Sera CA, SPS, LE, T1D b78 inhibits GAD enzyme activity Manto et al.35
(d)  Whole-cell patch-clamp 
technique on cerebellar 
slices
IgG from CSF CA Effects presynaptically with 
suppression of GABAergic 
transmission
Mitoma et al.,113 
Takenoshita 
et al.,72 Ishida 
et al.112
(e)  Whole-cell patch-clamp 
technique on hippocampal 
slices
Sera Epilepsy, T1D Increase of frequency of IPSPs Vianello et al.111
(f)  GAD-Abs in rat cerebellar 
slices
Sera, CSF SPS, T1D, 
autoimmune PS
SPS: reduction of GABA 
production
T1D/PS: NO differences in 
enzyme’s activity
Dinkel et al.15
(g)  Intracerebellar injection 
in rats
IgG from sera SPS, CA, 
paraneoplastic CA 
(GAD–), T1D
GAD+: altered cerebellar activity, 




(h)  Passive transfer of Abs 
in mice
GAD-Abs – Loss of GAD-EGFP neurons
NO behavioral changes
Chang et al.107
(i)  Intraventricular (i.c.v.) and 
intrathecal (i.th) injection
IgG SPS i.c.v.: stiffness-like behavior, 
impaired walking ability, 
sensorimotor dysfunction, 
normal anxiety test
i.th: NO motor symptoms; 
normal spinal transmission
Hansen et al.105
CA, cerebellar ataxia; CSF, cerebrospinal fluid; EGFP, enhanced green fluorescent protein; GABA, gamma-aminobutyric acid; GAD, glutamic acid 
decarboxylase; IPSP, Inhibitory  Postsynaptic Potentials; LE, Limbic encephalitis; PERM, progressive encephalomyelitis with rigidity and myoclonus; 
PS, polyendocrine syndrome; SPS, stiff person syndrome; T1D, DM-1.
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or in conjunction with baclofen and benzodiaz-
epines. In our experience, the most helpful agents 
in this family are gabapentin and vigabatrin, which 
act by inhibiting GABA-transaminase. Others 
include tiagabine, an inhibitor of GABA re-uptake, 
and levetiracetam, which facilitates inhibition of 
GABAergic transmission. Tizanidine, a centrally 
acting α2 adrenergic receptor, and dantrolene, a 
muscle relaxant, can also help.
If the above agents do not offer a satisfactory ben-
efit, we proceed to immunotherapy. The most 
widely used agent in this category is intravenous 
immunoglobulin (IVIg) after its proven efficacy. 
In a randomized, double-blinded, placebo-con-
trolled crossover trial we conducted in GAD-
positive SPS patients, IVIg resulted in significant 
improvements in objective stiffness parameters 
and activities of daily living.61 The duration of 
efficacy after each monthly IVIg infusion ranges 
from 4 to 12 weeks in most patients. IVIg remains 
the only immunomodulatory therapy with proven 
benefit in SPS. Subcutaneous immunoglobulin 
may be also an option in patients with poor 
venous access, or when there is a demonstrable 
early wearing-off effect, ensuring a more sus-
tained benefit. Plasmapheresis has been of limited 
and transient benefit and we do not routinely use 
it in spite of some anecdotal case reports.117 
Corticosteroids are surprisingly ineffective in our 
experience with a large number of patients, 
although one anecdotal report had shown limited 
benefit.118 Furthermore, triggering or exacerbat-
ing diabetes is a serious consideration that further 
limits its use. Of paramount importance is the 
control of diabetes, which requires insulin most 
times and, if uncontrolled, seems to worsen the 
neurologic symptomatology.
Immunosuppressive agents such as azathioprine, 
methotrexate, cyclophosphamide and mycophe-
nolate mofetil are equally disappointing, in spite 
of rare anecdotal reports.119,120 The most useful 
drug in this category is rituximab. A randomized 
controlled trial86 we conducted in patients with 
SPS demonstrated lack of efficacy of rituximab 
compared with placebo owing to a strong placebo 
effect. In this series, however, seven patients 
improved and four of them with severe disease 
demonstrated meaningful to impressive improve-
ments. On this basis, we believe rituximab is a 
useful drug for a subset of patients who have 
failed therapies with GABA-enhancing drugs and 
IVIg. It should be stressed that anti-GAD 
Table 3. Therapies of stiff person syndrome.
Symptomatic Immunologic








Can help most patients
High doses: not tolerated
IVIg The only proven 
immunomodulatory therapy: 
beneficial in SPS
GABAB agonists Baclofen Antispasticity drug
High doses my cause 
cognitive effects
Plasmapheresis Not routinely used: 




Tizanidine Muscle relaxant Corticosteroids Mostly ineffective


















against placebo, may have  
impressive benefits in some 
patients
GABA, gamma-aminobutyric acid; HSMT, Hematopoietic Stem Cell Transplantation; IVIg, intravenous immunoglobulin; SPS, stiff person syndrome.
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antibody titers may drop but not to a statistically 
significant level and the titers do not correlate or 
predict improvement.
Some SPS patients who failed conventional 
immunosuppressive therapy have experienced 
benefit after autologous hematopoietic stem cell 
transplantation (auto-HSCT). In one small study, 
three patients with SPS and one with PERM were 
initially treated with cyclophosphamide (Cy) 2 g/
m2 + Granulocyte-colony stimulating factors 
(G-CSF) and then conditioned with Cy 200 mg/
kg + Anti-thymocyte Globulin (ATG) followed by 
auto-HSCT. All patients tolerated the procedure 
well and showed improved physical performance. 
One patient’s walking distance improved from 
300 meters to 5 miles and one other’s ambulation 
improved from being confined to a wheelchair to 
being able to walk with a frame. Two patients 
became seronegative for anti-GAD antibodies and 
normalized their neurophysiological abnormali-
ties. Additional studies have also shown some 
benefit. Although auto-HSCT was thought prom-
ising, a large study aiming at 40 patients was ter-
minated early after recruiting 23 patients because 
of lack of efficacy or transient benefits, taking into 
account potential serious complications.121,122 
One of the many limitations of this study, as 
pointed out,123 was the enrollment of patients with 
advanced disease. A new Hematopoietic Stem 
Cell Transplantation (HSMT) trial in SPS 
patients unresponsive to the therapies mentioned 
above might be, however, considered for patients 
with still early disease, in a controlled trial design 
taking into account a strong placebo effect, and 
the use of objective validated scales.123
Therapy for the other, non-SPS, GAD-SDs
Therapeutic agents in autoimmune epilepsy, nys-
tagmus and cerebellar disease are the same in the 
other GAD-SDs as those discussed in SPS, except if 
their manifestation is acute or subacute, as seen in 
autoimmune encephalitis. In these circumstances, 
we start with intravenous steroids 1000 mg daily for 
5 days, followed by IVIg and rituximab, as needed. 
Anti-epileptics are added in patients with epilepsy, 
although GAD-associated epilepsy is reported 
refractory to the above immunomodulatory thera-
pies, often requiring more aggressive immunosup-
pressive approaches, with mycophenolate motefil or 
rituximab.59 Interestingly, exogenous testosterone 
replacement therapy has been shown to reduce sei-
zure frequency and intensity.124 In some cases, 
epilepsy surgery should be considered, although few 
beneficial surgical outcomes in GAD-associated 
epilepsy patients have been reported.59 Patients 
with longer-standing disease and those with cerebel-
lar ataxia, dysarthria and dysphagia have overall less 
impressive response to applied therapies.
Conclusion
The review highlights that high-titer anti-GAD 
antibodies are associated with an array of distinct 
neurological syndromes including SPS, cerebellar 
ataxia, epilepsy, limbic encephalitis, abnormal 
eye movements. Although high anti-GAD anti-
bodies in serum or their presence in CSF are 
important for diagnosis, the titers do not correlate 
with disease severity and do not generally predict 
response to immunotherapy. Despite considera-
ble efforts, using both in vitro and in vivo prepara-
tions, the pathophysiological role of anti-GAD 
antibodies has not yet been clarified, suggesting 
that other autoantibodies affecting inhibitory 
neurotransmission might be of importance, 
because autoimmunity targeting inhibitory syn-
aptic antigens point to a unifying theme of hyper-
excitability as the underlying pathomechanism.
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